Inhibrx Biosciences (INBX) Cash & Equivalents (2023 - 2025)
Historic Cash & Equivalents for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $153.1 million.
- Inhibrx Biosciences' Cash & Equivalents fell 2201.98% to $153.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $153.1 million, marking a year-over-year decrease of 2201.98%. This contributed to the annual value of $152.6 million for FY2024, which is 4509.43% down from last year.
- Per Inhibrx Biosciences' latest filing, its Cash & Equivalents stood at $153.1 million for Q3 2025, which was down 2201.98% from $186.6 million recorded in Q2 2025.
- Over the past 5 years, Inhibrx Biosciences' Cash & Equivalents peaked at $277.9 million during Q4 2023, and registered a low of $152.6 million during Q4 2024.
- Over the past 3 years, Inhibrx Biosciences' median Cash & Equivalents value was $196.3 million (recorded in 2024), while the average stood at $201.4 million.
- As far as peak fluctuations go, Inhibrx Biosciences' Cash & Equivalents crashed by 4509.43% in 2024, and later tumbled by 1776.11% in 2025.
- Quarter analysis of 3 years shows Inhibrx Biosciences' Cash & Equivalents stood at $277.9 million in 2023, then crashed by 45.09% to $152.6 million in 2024, then rose by 0.33% to $153.1 million in 2025.
- Its Cash & Equivalents stands at $153.1 million for Q3 2025, versus $186.6 million for Q2 2025 and $216.5 million for Q1 2025.